Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.60 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: metformin hydrochloride, metformin, me-344 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly mitochondrial quality control | 1.00 |
Knock down and overexpress NDUFA8 in a dopamine neuron, astrocyte and microglia tri-culture; measure PINK1–parkin mitophagy flux (mt-Keima) and phospho-ubiquitin (pS65-Ub) and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- PINK1–parkin mitophagy flux (mt-Keima) and phospho-ubiquitin (pS65-Ub)
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves PINK1–parkin mitophagy flux (mt-Keima) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of NDUFA8 in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: PINK1–parkin mitophagy flux (mt-Keima) and phospho-ubiquitin (pS65-Ub); dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Earlier readings: 2026-10-26 0.61; 2026-10-25 0.61; 2026-10-24 0.61; 2026-10-23 0.61.
Sealed predictions
- NDUFA8 in dopamine neurons, braak-0.02 (p 0.964) → +0.63 (p 0.067)receipt 0556
- NDUFA8 in dopamine neurons, resiliencen/a → n/areceipt 0080
- NDUFA8 in dopamine neurons, braakn/a → n/areceipt 0079
Swarm cases
receipt 0556: NDUFA8 in dopamine neurons, braak
- power
- full sample +0.35 (p 0.156, n 18), 95% CI -0.14 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.33 (p 0.179, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.35 (p 0.156, n 18). could be the mix.
- skeptic
- leave-one-out range +0.27 to +0.51, sign flips 0; without severely affected donors +0.35 (p 0.156, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NDUFA8 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0080: NDUFA8 in dopamine neurons, resilience
- cell type
- NDUFA8 is not measured in dopamine neurons; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for NDUFA8 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0079: NDUFA8 in dopamine neurons, braak
- cell type
- NDUFA8 is not measured in dopamine neurons; looking elsewhere.
- cell type
- strongest in glutamate neurons: -0.38 (p 4.1e-4, n 84). proposing glutamate neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NDUFA8 in dopamine neurons.
follow-up registered; not confirmed in ventral tegmental area.
follow-up NDUFA8 · glutamate neurons · braak: ventral tegmental area -0.31 p 0.0050 (needs p < 0.0038)
Receipts
loading the receipts